CCL17 AS CENTRAL IMMUNE REGULATOR – CCL17 INHIBITORS FOR USE IN T HELPER CELL-DRIVEN DISEASES
The current invention is based on the identification of the role of CCL17 in the genesis of T helper cell Th1-driven diseases, in particular atherosclerosis and autoimmune diseases.
The invention provides novel therapeutic approaches for treating atherosclerosis and other diseases such as myocardial infarction, stroke, peripheral vascular disease, chronic kidney disease and angina pectoris. These approaches are based on interfering with the interaction between the CCL17-cytokine and the CCL17-receptor. Respective agents will also be beneficial for the treatment of autoimmune diseases e.g. hypersensitivity dermatitis (CHS), psoriasis, rheumatoid arthritis, Bechterew's disease and inflammatory bowel disease (Crohn`s disease).
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
